Ten challenges in the management of neuroblastoma

Future Oncology

Volumn 8, Issue 7, 2012, Pages 839-858

  Gains, Jennifer ^a   Mandeville, Henry ^a   Cork, Nicholas ^a   Brock, Penelope ^b   Gaze, Mark ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

high dose chemotherapy; immunotherapy; international collaboration; molecular pathology; molecular radiotherapy; neuroblastoma; risk stratification; staging

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; FLUORODEOXYGLUCOSE F 18; GANGLIOSIDE GD2 MONOCLONAL ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; ISOTRETINOIN; LYM X SORB; MEDRONATE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH14.18; MORPHINE; MYC PROTEIN; PENTETREOTIDE IN 111; SODIUM THIOSULFATE; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

AGE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CAPILLARY LEAK SYNDROME; CHILDHOOD CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; GANGLIONEUROMA; GENE AMPLIFICATION; HEALTH CARE ACCESS; HISTOPATHOLOGY; HUMAN; HYPOTENSION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASM STAGING; NEUROBLASTOMA; NEUTROPENIA; PROGNOSIS; RADIOTHERAPY; RARE DISEASES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84864469883     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.70     Document Type: Review

References (107)

1. Spix C, Pastore G, Sankila R et al. Neuroblastoma incidence and survival in European children (1978-1997): Report from the Automated Childhood Cancer Information System project. Eur. J. Cancer 42, 2081-2091 (2006).
2. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D; European Neuroblastoma Study Group; Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group). High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol. 9(3), 247-256 (2008).
3. Ladenstein R, Valteau-Couanet D, Brock P et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during Rapid COJEC induction in pediatric patients with high-risk neuroblastoma: The European HR-NBL1/SIOPEN study. J. Clin. Oncol. 28, 3516-3524 (2010).
4. Matthay KK, Reynolds CP, Seeger RC et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group study. J. Clin. Oncol. 27, 1007-1013 (2009).
5. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: Results of German trials. Pediatr. Blood Cancer 56, 578-583 (2011).
6. Lehara T, Hosoi H, Akazawa K et al. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br. J. Cancer 94, 1510-1515 (2006).
7. Cohn SL, Pearson ADJ, London WB et al. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. J. Clin. Oncol. 27, 289-297 (2009).
8. Moroz V, Machin D, Faldum A et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project. Eur. J. Cancer 47, 561-571 (2011).
9. London WB, Castleberry RP, Matthay KK et al. Evidence for an age cut off greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J. Clin. Oncol. 23, 6459-6465 (2005).
10. De Bernadi B, Gerrard M, Boni L et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J. Clin. Oncol. 27, 1034-1040 (2009).
11. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 27(2), 374-378 (1971).
12. Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11(8), 1466-1477 (1993).
13. Monclair T, Brodeur GM, Ambros PF et al. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. J. Clin. Oncol. 27, 298-303 (2009).
14. Simon T, Hero B, Benz-Bohm G et al. Review of image defined risk factors on localized neuroblastoma patients: Results of the GPOH NB96 trial. Pediatr. Blood Cancer 50, 965-969 (2008).
15. De Bernardi B, Mosseri V, Rubie H et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br. J. Cancer 99, 1027-1033 (2008).
16. Bagatell R, Beck-Popovic M, London WB et al. Significance of MYCN amplification in International Neuroblastoma Staging System stage 1 and 2 neuroblastoma: A report from the International Neuroblastoma Risk Group database. J. Clin. Oncol. 27, 365-370 (2009).
17. Canete A, Gerrard M, Rubie H et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: The International Society of Pediatric Oncology European Neuroblastoma Experience. J. Clin. Oncol. 27, 1014-1019 (2009).
18. Attiyeh EF, London WB, Mossé YP et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353, 2243-2253 (2005).
19. Vermeulen J, De Preter K, Naranjo A et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: A retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 10, 663-671 (2009).
20. Ambros IS, Brunner B, Aigner G et al. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin. Cancer Res. 17, 792-804 (2011).
21. Schleiermacher G, Michon J, Ribeiro A et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br. J. Cancer 105, 1940-1948 (2011).
22. Kushner BH, LaQuaglia MP, Bonilla MA et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J. Clin. Oncol. 12, 2607-2613 (1994).
23. Cheung NK, Kushner BH, LaQuaglia M et al. N7: A novel multi-modality therapy of high-risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med. Pediatr. Oncol. 36, 227-230 (2001).
24. Schmidt M, Simon T, Hero B et al. The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97. Eur. J. Cancer 44, 1552-1558 (2008).
25. Valteau-Couanet D, Michon J, Boneu A et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J. Clin. Oncol. 23, 532-540 (2005).
26. Kohler JA, Ellershaw C, Machin D; Neuroblastoma Working Group of the Children's Cancer and Leukaemia Group. Response to N7 induction chemotherapy in children more than one year of age diagnosed with metastatic neuroblastoma treated in UKCCSG centers. Pediatr. Blood Cancer 49, 234-239 (2007).
27. Park JR, Scott JR, Stewart CF et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. J. Clin. Oncol. 29, 4351-4357 (2011).
28. De Ioris M, Castellano A, Ilari I et al. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma. Eur. J. Cancer 47, 572-578 (2011).
29. Veal GJ, Cole M, Errington J et al. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isoretinoin) in children with high-risk neuroblastoma - A study of the United Kingdom Children's Cancer Study Group. Br. J. Cancer 96, 424-431 (2007).
30. Villablanca JG, Krailo MD, Ames MM et al. Phase I trial of oral fenretinide in children with high risk solid tumours: A report from the Children's Oncology Group (CCG 09709). J. Clin. Oncol. 24, 3423-3430 (2006).
31. Garaventa A, Luksch R, Lo Piccolo MS et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin. Cancer Res. 9, 2032-2039 (2003).
32. Maurer BJ, Kalous O, Yesair DW et al. Improved oral delivery of N-(4-hydroxyphenyl) retinamide with a novel LYM-X-SORB organized lipid complex. Clin. Cancer Res. 13, 3079-3086 (2007).
33. Gilman AL, Ozkaynak MF, Matthay KK et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem cell rescue: A report from the Children's Oncology Group. J. Clin. Oncol. 27, 85-91 (2009).
34. Ozkaynak MF, Sondel PM, Krailo MD et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study. J. Clin. Oncol. 18, 4077-4085 (2000).
35. Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isoretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324-1334 (2010).
36. Castel V, Segura V, Cañete A. Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clin. Transl Oncol. 12, 788-793 (2010).
37. Brisse HJ, McCarville MB, Granata C et al. Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group Project. Radiology 261, 243-257 (2011).
38. Matthay KK, Shulkin B, Ladenstain R et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force. Br. J. Cancer 102, 1319-1326 (2010).
39. Melzer HI, Coppenrath E, Schmid I et al. 123I-mIBG scintigraphy/SPECT versus 18F FDG PET in paediatric neuroblastoma. Eur. J. Nucl. Med. Mol. Imaging 38, 1648-1658 (2011).
40. Sharp SE, Shulkin BL, Gelfand MJ et al. 123I-mIBG scintigraphy and 18F-FDG PET in neuroblastoma. J. Nucl. Med. 50, 1237-1243 (2009).
41. Papathanasiou ND, Gaze MN, Sullivan P et al. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: Diagnostic comparison and survival analysis. J. Nucl. Med. 52, 519-525 (2011).
42. Taggart DR, Han MM, Quach A et al. Comparison of iodine-123 metaiodobenzylguanidine (mIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 mIBG therapy for relapsed neuroblastoma. J. Clin. Oncol. 27, 5343-5349 (2009).
43. Kroiss A, Putzer D, Uprimny C et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur. J. Nucl. Med. Mol. Imaging 38, 865-873 (2011).
44. Fiebrich HB, Brouwers AH, Kerstens MN et al. 6-[F-18]fluoro-l- dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123) I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J. Clin. Endocrinol. Metab. 94, 3922-3930 (2009).
45. Timmers HJ, Chen CC, Carrasquillo JA et al. Comparison of 18F-fluoro-l-DOPA, 18F fluoro-deoxyglucose, and 18F-flurodopamine PET and 123I-mIBG scintigraphy in the localization of phaeochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 94, 4757-4767 (2009).
46. Piccardo A, Lopci E, Conte M et al. Comparison of 18F-dopa PET/CT and 123I-mIBG scinitigraphy in stage 3 and 4 neuroblastoma: A pilot study. Eur. J. Nucl. Med. Mol. Imaging 39, 57-71 (2012).
47. Beiske K, Burchill SA, Cheung IY et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: Recommendations by the International Neuroblastoma Risk Group Task Force. Br. J. Cancer 100, 1627-1637 (2009).
48. Garaventa A, Parodi S, De Bernardi B et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur. J. Cancer 45, 2835-2842 (2009).
49. London WB, Castel V, Monclair T et al. Clinical and biological features predictive of survival after relapse of neuroblastoma: A report from the International Neuroblastoma Risk Group Project. J. Clin. Oncol. 29, 3286-3292 (2011).
50. Rubie H, Chisholm J, Defachelles AS et al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A joint Socié té Fraņais des Cancers De l'Enfant and United Kingdom Children Cancer Study Group - New Agents Group Study. J. Clin. Oncol. 24, 5259-5264 (2006).
51. Vassal G, Giammarile F, Brooks M et al. A Phase II study of irinotecan in children with relapsed or refractory neuroblastoma: A European cooperation of the Société Fraņais d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur. J. Cancer 44, 2453-2460 (2008).
52. Garaventa A, Luksch R, Biasotti S et al. A Phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 98, 2488-2494 (2003).
53. Simon T, Längler A, Berthold F et al. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: Results of a Phase 2 trial. J. Pediatr. Hematol. Oncol. 29, 101-106 (2007).
54. Simon T, Längler A, Harnischmacher U et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a Phase-II trial. J. Cancer Res. Clin. Oncol. 133, 653-661 (2007).
55. Wagner LM, Villablanca JG, Stewart CF et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study. J. Clin. Oncol. 27, 1290-1296 (2009).
56. Rubie H, Georger B, Frappaz D et al. Phase I study of topotecan in combination with temozolamide (TOTEM) in relapsed or refractory paediatric solid tumours. Eur. J. Cancer 46, 2763-2770 (2010).
57. London WB, Frantz CN, Campbell La et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group Study. J. Clin. Oncol. 28, 3808-3815 (2010).
58. Bagatell R, London WB, Wagner LB et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group Study. J. Clin. Oncol. 29, 208-213 (2011).
59. Kushner BH, Kramer K, Modak S et al. High-dose carboplatin-irinotecan- temozolomide: Treatment option for neuroblastoma resistant to topotecan. Pediatr. Blood Cancer 56, 403-408 (2011).
60. Kushner BH, Kramer K, Modak S et al. High-dose cyclophosphamide- irinotecan- vincristine for primary refractory neuroblastoma. Eur. J. Cancer 47, 84-89 (2011).
61. Kushner B, Kramer K, Modak S, Qin L, Cheung N. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer 116, 3054-3060 (2010).
62. Minturn JE, Evans AE, Villablanca JG et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study. Cancer Chemother. Pharmacol. 68, 1057-1065 (2011).
63. Fouladi M, Park JR, Stewart CF et al. Pediatric Phase I trial and pharmacokinetic study of vorinostat: A Children's Oncology Group Phase I Consortium Report. J. Clin. Oncol. 28, 3623-3629 (2010).
64. Fox E, Aplenc R, Bagatell R et al. A Phase I trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor inhibitor, in children and adolescents with refractory solid tumors. J. Clin. Oncol. 35, 5174-5181 (2010).
65. Fox E, Maris JM, Cohn SL et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother. Pharmacol. 66, 737-743 (2010).
66. Spunt SL, Grupp SA, Vik TA. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J. Clin. Oncol. 29, 2933-2940 (2011).
67. Geoerger B, Kieran MW, Grupp S et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur. J. Cancer 48, 253-262 (2012).
68. Øra I, Eggert A. Progress in treatment and risk stratification of neuroblastoma: Impact on future clinical and basic research. Semin. Cancer Biol. 21, 217-228 (2011).
69. Russell HZ, Groshen SG, Ara T et al. A Phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Study. Pediatr. Blood Cancer 57, 275-282 (2011).
70. Matthay KK, Yanik G, Messina J et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J. Clin. Oncol. 25, 1054-1060 (2007).
71. Matthay KK, Tan JC, Villablanca JG et al. Phase I dose escalation of iodine-131- metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study. J. Clin. Oncol. 24, 500-506 (2006).
72. Matthay KK, Quach A, Huberty J et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I study. J. Clin. Oncol. 27, 1020-1025 (2009).
73. Gaze M, Chang Y, Flux G et al. Feasibility of dosimetry based high dose 131mIBG with topotecan as a radiosensitiser in children with metastatic neuroblastoma. Cancer Biother. Radiopharm. 20(2), 195-199 (2005).
74. More SS, Itsara M, Yang X et al. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model. Clin. Cancer Res. 17, 2339-2349 (2011).
75. Menda Y. O'Dorisio M.S. Madsen M. et al. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumours that express somatostatin receptors J. Nucl. Med. 1524-1531 2010.
76. Menda Y, O'Dorisio MS, Madsen M et al. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumours that express somatostatin receptors. J. Nucl. Med. 51, 1524-1531 (2010) 76. Gains JE, Bomanji JB, Fersht NL et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J. Nucl. Med. 52, 1041-1047 (2011).
77. Kramer K, Kushner B, Heller G, Cheung NK. Neuroblastoma metastatic to the central nervous system. Cancer 91, 1510-1519 (2001).
78. Kushner BH, Kramer K, Modak S et al. Topotecan, thiotepa, and carboplatin for neuroblastoma: Failure to prevent relapse in the central nervous system. Bone Marrow Transplant. 37, 271-276 (2006).
79. Kramer K, Kushner BH, Modak S et al. Compartmental intrathecal radioimmunotherapy: Results for treatment for metastatic CNS neuroblastoma. J. Neurooncol. 97, 409-418 (2010).
80. Croog VJ, Kramer K, Cheung NK et al. Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma. Int. J. Radiat. Oncol. Biol. Phys. 78, 849-854 (2010).
81. Rubie H, De Bernadi B, Gerrard M et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: Results of the prospective INES 99.1. J. Clin. Oncol. 29, 449-455 (2010).
82. Kushner B, Budnick A, Kramer K et al. Ototoxicity form high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107, 417-422 (2006).
83. Neuwelt EA, Brock P. Critical need for international consensus on ototoxicity assessment criteria. J. Clin. Oncol. 28, 1630-1632 (2010).
84. Li Y, Womer RB, Siber JH. Predicting cisplatin ototoxicity in children: The influence of age and cumulative dose. Eur. J. Cancer 40, 2445-2451 (2004).
85. Fisher MJ, Lange BJ, Needle MN et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr. Blood Cancer 43, 780-784 (2004).
86. Katzenstein HM, Chang K, Krailo M et al. A randomized study of platinum based chemotherapy with or without amifostine for the treatment of children with hepatoblastoma (HB): A report of the Intergroup Hepatoblastoma Study P9645. Am. Soc. Clin. Oncol. 22(14 Suppl.), Abstract 8518 (2004).
87. Marina N, Chang KW, Malogolowkin M et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors. A Children's Oncology Group Study. Cancer 104, 841-847 (2005).
88. Fouladi M, Chintagumpala M, Ashley D et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medullobalstoma. J. Clin. Oncol. 26, 3749-3755 (2008).
89. Simon T, Hero B, Bongartz R et al. Intensified external beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1 with residual local disease. Strahlenther. Onkol. 182, 389-394 (2006).
90. Gatcombe HG, Marcus RB Jr, Katzenstein HM et al. Excellent local control from radiation therapy for high-risk neuroblastoma. Int. J. Radiat. Oncol. Biol. Phys. 74(5), 1549-1554 (2009).
91. Pai Panandiker AS, McGregor L, Krasin MJ et al. Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma. Int. J. Radiat. Oncol. Biol. Phys. 76(4), 1161-1165 (2010).
92. Paulino AC, Ferenci MS, Chiang KY et al. Comparison of conventional to intensity modulated radiation therapy for abdominal neuroblastoma. Pediatr. Blood Cancer 46, 739-744 (2006).
93. Shaffer R, Vollans E, Vellani R et al. A radiotherapy planning study of RapidArc, intensity modulated radiotherapy, three-dimensional conformal radiotherapy, and parallel opposed beams in the treatment of pediatric retroperitoneal tumors. Pediatr. Blood Cancer 56, 16-23 (2011).
94. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiat. Oncol. Biol. Phys. 65, 1-7 (2006).
95. Schneider U, Lomax A, Timmermann B. Second cancers in children treated with modern radiotherapy techniques. Radiother. Oncol. 89, 135-140 (2008).
96. Hattangadi JA, Rombi B, Yock TI et al. Proton radiotherapy for high-risk pediatric neuroblastoma: Early outcomes and dose comparison. Int. J. Radiat. Oncol. Biol. Phys. 83(3), 1015-1022 (2012).
97. Laverdière C, Liu Q, Yasui Y et al. Long-term outcomes in survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. J. Natl Cancer Inst. 101, 1131-1140 (2009).
98. Perwein T, Lackner H, Sovinz P et al. Survival and late effects in children with stage 4 neuroblastoma. Pediatr. Blood Cancer 57, 629-635 (2001).
99. Grunfeld E. Looking beyond survival: How are we looking at survivorship? J. Clin. Oncol. 24, 5166-5169 (2006).
100. Meadows AT. Pediatric cancer survivorship: Research and clinical care. J. Clin. Oncol. 24, 5160-5165 (2006).
101. Conte M, Parodi S, De Bernardi B et al. Neuroblastoma in adolescents: The Italian experience. Cancer 106(6), 1409-1417 (2006).
102. Castel V, Villamón E, Cañete A et al. Neuroblastoma in adolescents: Genetic and clinical characterisation. Clin. Transl Oncol. 12(1), 49-54 (2010).
103. Esiashvili N, Goodman M, Ward K, Marcus RB Jr, Johnstone PA. Neuroblastoma in adults: Incidence and survival analysis based on SEER data. Pediatr. Blood Cancer 49, 41-46 (2007).
104. Podda MG, Luksch R, Polastri D et al. Neuroblastoma in patients over 12 years old: A 20-year experience at the Istituto Nazionale Tumori of Milan. Tumori 96(5), 684-689 (2010).
105. Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK. Response, survival, and toxicity after iodine-131- metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer 117, 4286-4293 (2011).
106. Hansard HC. Vol. 502, Col. 308WH-314WH (16 December 2009).
107. Hansard HC. Vol. 507, Col. 226WH-232WH (16 March 2010).